ClinicalTrials.gg
RecruitingNCT06359418Updated Aug 22, 2025

Acupuncture for Prediabetes With Combined Obesity

An interventional study of Acupuncture and Sham acupuncture in Obesity, Abdominal Obesity and PreDiabetes, sponsored by Guang'anmen Hospital of China Academy of Chinese Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-08-22.

Primary conditionObesity, AbdominalRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Abdominal
Why
  1. The study's listed conditions name Obesity, Abdominal, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Obesity, Abdominal with a site in China — 6 open to participants now, 7 under way, 1 of them phase 3. Obesity, Abdominal · China.

Planned enrollment
6th of 17
260 · median 120
Started
2025
with 2 others
No phase
12 of 19
5 open now
Registered
13th of 19
by date
Lead sponsor
1 of 19
Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Among the 19 studies in Obesity, Abdominal with a site in China, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2025, is one of 12 with no phase, and was the 13th registered.

Obesity, Abdominal

295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.

Browse Obesity, Abdominal studies →

Open to participants now

6 of the 19 studies in Obesity, Abdominal with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 26 Obesity, Abdominal studies recruiting now, 3 (12%) set no upper age limit and 21 (81%) stop at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Obesity, Abdominal with a site in China, or all of them as a file.
02

Study summary

The clinical trial aims to evaluate the efficacy and safety of acupuncture in reducing weight and waist circumference while modulating glucose and lipid metabolism in Prediabetes with Combined Obesity.

03

Conditions studied

  • Obesity
  • Abdominal Obesity
  • PreDiabetes

Browse trials for

Keywords

  • acupuncture
  • randomized controlled trial
  • Obesity
  • Abdominal Obesity
  • PreDiabetes
04

In context

Obesity, Abdominal Reclassified

295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.

This study's planned enrollment of 260 is above the median of 58 across 235 interventional studies indexed under Obesity, Abdominal.

Browse Obesity, Abdominal studies →

Lead sponsor

Guang'anmen Hospital of China Academy of Chinese Medical Sciences is the lead sponsor of 137 studies on the registry; 37 are open to participants now.

Compared within Obesity, Abdominal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Subjects are eligible to be included in the trial only if all of the following criteria apply:

  1. Simultaneously meeting the diagnostic criteria for both general obesity, abdominal obesity, and prediabetes;
  2. Aged 18-64 years old;
  3. obtained before any trial-related activities.

Exclusion criteria

Exclusion Criteria:

-

Subjects are excluded from the trial if any of the following criteria apply:

  1. Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome, established Polycystic Ovary Syndrome);
  2. impaired glucose regulation due to hyperthyroidism, endocrine tumors and extensive liver damage;
  3. Diagnosis of type 1 or type 2 diabetes per the judgment of the investigator;
  4. Current or history of treatment with medications that may cause significant weight gain, within 3 months prior to screening, including systemic (except for a short course of treatment, i.e. 7-10 days), antidepressants, antipsychotic, mood stabilizers, antiepileptic and hormone ;
  5. History of pancreatitis or pancreatectomy;
  6. Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device;
  7. Current participation (or within the last month) in an organized weight reduction program or currently using or used medication for obesity or hyperglycemia within 3 months before screening: liraglutide, exenatide, pramlintide, orlistat, topiramate, phenteremine, or metformin (either by prescription or as part of a clinical trial);
  8. A self-reported change in body weight >5 kg within 3 months before screening irrespective of medical records;
  9. Serious medical conditions (including but not limited to ongoing renal or hepatic insufficiency, congestive heart failure, myocardial infarction, stroke, hematopoietic system diseases, progressive malignant tumor or other serious consumptive diseases); history of angina pectoris, , claudication, or acute limb ischemia within the past 6 months prior to screening;
  10. Serious psychiatric illness, including lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, and anorexia nervosa; current serious personality disorder, (e.g. borderline or antisocial), current severe major depressive disorder, recent (previous 6 months) suicide attempt or current active suicidal ideation, recent hospitalization due to psychiatric illness;
  11. Skin infection, blood coagulation disorders and other conditions that are not suitable for acupuncture;
  12. Metal allergies or severe fear of needles;
  13. Pregnant or breast-feeding women or planning to become pregnant during the study period;
  14. Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Acupuncture

    The participants in the acupuncture group will receive treatment that consists of 28 acupuncture sessions over a 12-week (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 8 weeks) period after baseline, each for 30 minutes. Hwato brand disposable acupuncture needles (size 0.30 x75mm; size 0.30 x 50mm; size 0.30 x 40mm) will be used. BaiHui(DU20), YinTang(EX-HN3), ShuaiGu(GB8), QuChi ( LI11), ZhongWan(RN12), XiaWan(RN10), TianShu(ST25), GuanYuan(RN4), FengLong(ST40), Daimai(GB26) and Fujie(SP14) were selected as acupoints protocol. At the same time, all participants will receive standardized lifestyle intervention counseling from randomization to end of whole study period, about once a month. Participants were advised to achieve a reduced-calorie diet (500-kcal deficit per day relative to the energy expenditure estimated at the time they underwent randomization) and increased physical activity (with 150 minutes per week of physical activity).

    Device: Acupuncture

  • Sham comparator
    Sham acupuncture

    The participants in the sham acupuncture group will receive shallow needling at sham DU20, EX-HN3, GB8, LI11, RN12, RN10, ST25, RN4, ST40, GB26 and SP14. The protocol includes the same duration and frequency of sessions as for the acupuncture treatment, but the treatment was delivered superficially at non-acupuncture points 10-20 mm to the lateral of corresponding acupuncture and not above a meridian line. The Hwato brand disposable acupuncture needles(size 0.20 x25mm) will be inserted. At the same time, all participants will receive standardized lifestyle intervention counseling from randomization to end of whole study period, about once a month. Participants were advised to achieve a reduced-calorie diet (500-kcal deficit per day relative to the energy expenditure estimated at the time they underwent randomization) and increased physical activity (with 150 minutes per week of physical activity).

    Device: Sham acupuncture

Interventions

  • DeviceAcupuncture

    The acupuncture needle (size 0.30x40mm) will be inserted into DU20, EX-HN3 and GB8 acupoints at the depth of 15-30mm; The acupuncture needle (size 0.30x50mm or size 0.30x75mm) will be inserted into other acupoints at the depth of 40-70mm; Manipulation will be done after insertion (6 times of small amplitude and uniform twist).

  • DeviceSham acupuncture

    The acupuncture needle (size 0.20x25mm) will be inserted into all acupoints at the depth of 2mm without any manipulation.

07

What researchers measure

Primary outcomes

  1. The percentage change in body weight from baseline to week 12

    The weight is measured by electronic scale with an accuracy of 0.1kg.

    Time frame: week 12

  2. The percentage change in waist circumference from baseline to week 12

    The waist circumference is measured by a fiberglass tape measure with an accuracy of 0.1 centimeters.

    Time frame: week 12

Secondary outcomes

  1. The percentage change in body weight compared to the baseline

    The weight is measured by electronic scale with an accuracy of 0.1kg.

    Time frame: week 4, week 8, week 16, week 20, week 24, week 28, week 32, week 36, week 52

  2. The percentage change in waist circumference compared to the baseline

    Waist circumference measurements are accurate to 0.1cm.

    Time frame: week 4, week 8, week 16, week 20, week 24, week 28, week 32, week 36, week 52

  3. Achievement of a reduction in body weight of 5% or more compared to the baseline

    A 5% reduction is the weight loss target for obese patients recommended in most guidelines.

    Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52

  4. Achievement of a reduction in body weight of 7% or more compared to the baseline

    A 7% reduction is a weight loss target for obese patients with other metabolic diseases recommended in most guidelines.

    Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52

  5. The change in body weight from baseline

    The weight is measured by electronic scale with an accuracy of 0.1kg.

    Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52

  6. The change in waist circumference from baseline

    Waist circumference measurements are accurate to 0.1cm.

    Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52

  7. The proportion of participants reverting to normoglycaemia

    The determination is based on the results of blood glucose laboratory parameters.

    Time frame: week 12, week 36, week 52

  8. The proportion of participants developing diabetes

    The determination is based on the results of blood glucose laboratory parameters.

    Time frame: week 12, week 36, week 52

  9. The change in 2hPG from baseline and percentage of patients who returned to normal

    2hPG, 2-hour post-load Plasma Glucose, will be measured by oral glucose tolerance test, in mmol/L.

    Time frame: week 12, week 36, week 52

  10. The change in FPG from baseline and percentage of patients who returned to normal

    FPG is fasting plasma glucose, the result will be reported in mmol/L.

    Time frame: week 12, week 36, week 52

  11. The change in HbA1c from baseline and percentage of patients who returned to normal

    HbA1c is glycated haemoglobin, the result will be reported in percentage (%) units.

    Time frame: week 12, week 36, week 52

  12. The change in 1hPG from baseline and percentage of patients who returned to normal

    1hPG, 1-hour post-load Plasma Glucose, will be measured by oral glucose tolerance test, in mmol/L.

    Time frame: week 12, week 36, week 52

  13. Changes in appetite VAS score from baseline

    VAS=visual analogue scale; The VAS of appetite is a 100mm with two ends pointing to "none" and "difficult to control", respectively, and the subjects mark them on the online segment according to their perception. Appetite is quantitatively evaluated by measuring the distance from the left side of the segment to the marked point.

    Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52

  14. The change in BMI from baseline

    BMI=Body Mass Index, weight and height will be combined to report BMI in kg/m\^2.

    Time frame: week 4, week 8, week 12, week 16, week 24, week 36, week 52

  15. The change in WHR from baseline

    WHR=Waist-to-Hip Ratio, the ratio of waist to hip circumference, waist and hip circumference are accurate to 0.1cm.

    Time frame: week 4, week 8, week 12, week 16, week 24, week 36, week 52

  16. The change in WHtR from baseline

    WHtR=waist-to-Height Ratio, the ratio of waist circumference to height. Both are in cm units, accurate to 0.1cm.

    Time frame: week 4, week 8, week 12, week 16, week 24, week 36, week 52

  17. The change in FINS from baseline

    FINS is fasting insulin, the result will be reported in pmol/L.

    Time frame: week 12, week 36, week 52

  18. The change in HOMA-IR from baseline

    HOMA, Homeostatic Model Assessment, is a mathematical model reflecting the interaction of glucose and insulin in different organs (including pancreas, liver, and surrounding tissues). lt was first proposed by Matthews in 1985. Insulin Resistance (HOMA-IR) will be evaluated by fasting plasma glucose (FPG) and fasting insulin (FlNS). The calculation method is HOMA-IR=FPG xFINS/22.5.

    Time frame: week 12, week 36, week 52

  19. The change in HOMA-β from baseline

    HOMA, Homeostatic Model Assessment, is a mathematical model reflecting the interaction of glucose and insulin in different organs (including pancreas, liver, and surrounding tissues). lt was first proposed by Matthews in 1985. Islet β cell function (HOMA-β ) will be evaluated by fasting plasma glucose (FPG) and fasting insulin (FlNS). The calculation method is HOMA- β = 20 x FINS/ (FPG-3.5).

    Time frame: week 12, week 36, week 52

  20. The change in Serum total cholesterol from baseline

    The Serum total cholesterol will be reported in mmol/L.

    Time frame: week 12, week 36, week 52

  21. The change in Triglyceride from baseline

    The Triglyceride will be reported in mmol/L.

    Time frame: week 12, week 36, week 52

  22. The change in Low-Density Lipoprotein Cholesterol from baseline

    The Low-Density Lipoprotein Cholesterol will be reported in mmol/L.

    Time frame: week 12, week 36, week 52

  23. The change in High-Density Lipoprotein Cholesterol from baseline

    The High-Density Lipoprotein Cholesterol will be reported in mmol/L.

    Time frame: week 12, week 36, week 52

  24. The change in Serum Uric Acid from baseline

    The Serum Uric Acid will be reported in μmol/L.

    Time frame: week 12, week 36, week 52

  25. The change in C-reactive protein from baseline

    The C-reactive protein will be reported in mg/L.

    Time frame: week 12, week 36, week 52

  26. The change in blood pressure from baseline

    Record the values of systolic blood pressure and diastolic blood pressure in mmHg.

    Time frame: week 4, week 8, week 12, week 16, week 24, week 36, week 52

  27. Changes of the score of the European five-dimensional Health scale (EQ-5D-5L) compared with the baseline.

    EQ-5D-5L=European Quality of Life Five Dimension Five Level Scale Questionnaire. The questionnaire which is widely used to evaluate the quality of life of the general population is divided into two parts: EQ-5D health description system and EQ-VAS. The score was calculated by calculating formula according to the choices made by the subjects in the questionnaire.

    Time frame: week 12, week 36

  28. Changes of the PHQ-4 score from the baseline.

    PHQ-4=patient health questionnaire-4. PHQ-4 consists of the first two items in PHQ-9 (PHQ-2) and the first two items in GAD-7 (GAD-2), including depression and anxiety. It is translated into Chinese by scholars and verified by scholars. It has good reliability and validity and is suitable for depression and anxiety screening.

    Time frame: week 12, week 36

Other outcomes

  1. Expectance assessment

    Participants will be asked the following question: What do you think will happen to your obesity and prediabetes in 3 months?

    Time frame: baseline

  2. Assessment of belief in acupuncture

    Participants will be asked to answer "do you think acupuncture is helpful for obesity and prediabetes?" And three other related questions.

    Time frame: baseline

  3. Blinding assessment

    Participants will be asked the following question: do you think you have received traditional acupuncture in the past weeks?

    Time frame: week 12

  4. Safety assessment

    Adverse events and severe adverse events will be recorded in the case report form, whether related to interventions ol not.

    Time frame: week 0 to week 52

  5. Adherence assessment of acupuncture

    Adherence will be assessed via counting treatment sessions. Those who complete over 80% treatment sessions will be defined as of good adherence.

    Time frame: weeks 1 to week 12

  6. Adherence assessment of life modification

    Adherence will be assessed through dietary diaries and physical activity questionnaires.

    Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2027, 27 months after the start.

Of 107 non-industry interventional studies with no phase under Obesity, Abdominal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 27 months is above that.

Counting every sponsor, half of 117 studies reached it within 16 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2024
First posted
Apr 11, 2024
StartActual
Mar 1, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Apr 1, 2028
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06359418
Collaborators
Hubei Hospital of Traditional Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Zhuhai, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Dongfang Hospital Beijing University of Chinese Medicine, Linyi Hospital of Traditional Chinese Medicine, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Xi'an Traditional Chinese Medicine Hospital, Qingdao Traditional Chinese Medicine Hospital, Xi'an Hospital of Traditional Chinese Medicine, Heilongjiang Academy of traditional Chinese Medicine, The Affiliated Hospital of Qingdao University, Yantai Penglai Traditional Chinese Medicine Hospital, Shaanxi Hospital of Traditional Chinese Medicine
Responsible party
Liu Zhishun (Principal Investigator, Guang'anmen Hospital of China Academy of Chinese Medical Sciences) — Principal investigator
First posted
Apr 11, 2024
Start date
Mar 1, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Aug 22, 2025

Study contacts

Zhishun Liu, PhD
Contact
zhishunjournal@163.com
86-010-88002331
Yan Yan
Contact
yanyanxuexi@163.com
+8618579122011
Zhishun Liu, PhD
principal investigator · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion